Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

PURPOSE: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ghobrial, Irene M., Gertz, Morie, LaPlant, Betsy, Camoriano, John, Hayman, Suzanne, Lacy, Martha, Chuma, Stacey, Harris, Brianna, Leduc, Renee, Rourke, Meghan, Ansell, Stephen M., DeAngelo, Daniel, Dispenzieri, Angela, Bergsagel, Leif, Reeder, Craig, Anderson, Kenneth C., Richardson, Paul G., Treon, Steven P., Witzig, Thomas E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2010
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834498/
https://ncbi.nlm.nih.gov/pubmed/20142598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.0994
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares